Clinical Trials
205
24 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Completed
113
55.1%
Not yet recruiting
24
11.7%
Recruiting
68
33.2%
No approval data available
- HKBU's Institute of Creativity and School of Chinese Medicine hosted the inaugural "CxC" Series session on 11 August, themed around autophagy and its potential against neurodegenerative diseases. - Professor Noboru Mizushima of The University of Tokyo outlined autophagy's molecular mechanisms and reversible ATG knockdown mouse models showing restored motor and memory functions. - Professor Li Min presented HKBU's discovery of autophagy-regulating neuroprotective agents derived from Uncaria rhynchophylla (Gouteng) and curcumin derivatives. - The event highlighted how traditional Chinese medicine wisdom is integrating with molecular science to address the rising global prevalence of Alzheimer's and Parkinson's diseases.
- Shimadzu Corporation has invested in OptQC Inc., a University of Tokyo spinout, through its Shimadzu Future Innovation Fund corporate venture capital arm. - OptQC is developing optical quantum computers that operate at room temperature and atmospheric pressure, reducing energy consumption compared to superconducting systems. - The technology is expected to solve complex computational problems with potential applications in drug discovery, materials development, and semiconductor research. - OptQC was selected for a NEDO project in 2025, and its first system was installed at AIST in July 2026.
- Anbogen Therapeutics and The University of Tokyo entered a Collaborative Research Agreement to evaluate ABT-301 (Imofinostat), a selective Class I HDAC inhibitor, across multiple solid tumor types using veterinary oncology models. - The collaboration will assess ABT-301 as monotherapy and in combination with other agents in osteosarcoma, melanoma, soft tissue sarcoma, bladder cancers, and other refractory solid tumors. - Naturally occurring canine cancers, particularly osteosarcoma, are clinically and molecularly analogous to human tumors, enabling translational data to inform human indication expansion and trial design. - ABT-301 is currently in a Phase I/II trial combined with anti-PD-1 and anti-VEGF for pMMR/non-MSI-High metastatic colorectal cancer, with the partnership aimed at extending its clinical potential into new indications.
